BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27450902)

  • 21. Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles.
    Das S; Mukherjee P; Chatterjee R; Jamal Z; Chatterji U
    Mol Cancer Ther; 2019 Mar; 18(3):680-692. PubMed ID: 30587555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PEGylated hydrazided gold nanorods for pH-triggered chemo/photodynamic/photothermal triple therapy of breast cancer.
    Xu W; Qian J; Hou G; Wang Y; Wang J; Sun T; Ji L; Suo A; Yao Y
    Acta Biomater; 2018 Dec; 82():171-183. PubMed ID: 30336271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous Targeting of Differentiated Breast Cancer Cells and Breast Cancer Stem Cells by Combination of Docetaxel- and Sulforaphane-Loaded Self-Assembled Poly(D, L-lactide-co-glycolide)/Hyaluronic Acid Block Copolymer-Based Nanoparticles.
    Huang J; Tao C; Yu Y; Yu F; Zhang H; Gao J; Wang D; Chen Y; Gao J; Zhang G; Zhou G; Liu J; Sun Z; Sun D; Zou H; Xu H; Lu Y; Zhong Y
    J Biomed Nanotechnol; 2016 Jul; 12(7):1463-77. PubMed ID: 29337484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
    Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
    Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer stem cell: the roles and therapeutic implications.
    Yang F; Xu J; Tang L; Guan X
    Cell Mol Life Sci; 2017 Mar; 74(6):951-966. PubMed ID: 27530548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SURVIVIN as a marker for quiescent-breast cancer stem cells-An intermediate, adherent, pre-requisite phase of breast cancer metastasis.
    Siddharth S; Das S; Nayak A; Kundu CN
    Clin Exp Metastasis; 2016 Oct; 33(7):661-75. PubMed ID: 27411340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer.
    Zhang L; Xu L; Zhang F; Vlashi E
    Cell Cycle; 2017 Apr; 16(8):737-745. PubMed ID: 27753527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.
    Li M; Pan M; You C; Zhao F; Wu D; Guo M; Xu H; Shi F; Zheng D; Dou J
    Breast Cancer Res; 2020 Mar; 22(1):26. PubMed ID: 32143670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dual-targeted hyaluronic acid-gold nanorod platform with triple-stimuli responsiveness for photodynamic/photothermal therapy of breast cancer.
    Xu W; Qian J; Hou G; Wang Y; Wang J; Sun T; Ji L; Suo A; Yao Y
    Acta Biomater; 2019 Jan; 83():400-413. PubMed ID: 30465921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-targeting CuS nanoparticles for multimodal imaging and guided photothermal therapy of lymph node metastasis.
    Shi H; Yan R; Wu L; Sun Y; Liu S; Zhou Z; He J; Ye D
    Acta Biomater; 2018 May; 72():256-265. PubMed ID: 29588255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
    Croker AK; Goodale D; Chu J; Postenka C; Hedley BD; Hess DA; Allan AL
    J Cell Mol Med; 2009 Aug; 13(8B):2236-2252. PubMed ID: 18681906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals.
    Li R; Hu X; Shang F; Wu W; Zhang H; Wang Y; Pan J; Shi S; Dong C
    Acta Biomater; 2022 Aug; 148():218-229. PubMed ID: 35705171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy.
    Li Y; Liu G; Ma J; Lin J; Lin H; Su G; Chen D; Ye S; Chen X; Zhu X; Hou Z
    J Control Release; 2017 Jul; 258():95-107. PubMed ID: 28501673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway.
    Chen J; Chang H; Peng X; Gu Y; Yi L; Zhang Q; Zhu J; Mi M
    Sci Rep; 2016 Jun; 6():28858. PubMed ID: 27345219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram.
    Sun T; Yang W; Toprani SM; Guo W; He L; DeLeo AB; Ferrone S; Zhang G; Wang E; Lin Z; Hu P; Wang X
    Cell Commun Signal; 2020 Mar; 18(1):36. PubMed ID: 32138738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
    Dillard C; Kiyohara M; Mah V; McDermott SP; Bazzoun D; Tsui J; Chan AM; Haddad G; Pellegrini M; Chang YL; Elshimali Y; Wu Y; Vadgama JV; Kim SR; Goodglick L; Law SM; Patel DD; Dhawan P; O'Brien NA; Gordon LK; Braun J; Lazar G; Wicha MS; Wadehra M
    Mol Cancer Ther; 2020 Aug; 19(8):1682-1695. PubMed ID: 32451329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
    Chen JH; Huang WC; Bamodu OA; Chang PM; Chao TY; Huang TH
    BMC Cancer; 2019 Jun; 19(1):634. PubMed ID: 31248373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
    Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.